Richard Morgan, PhD


As a member of the team that published the first approved human gene transfer experiment in 1990 (N. Engl. J. Med. 323:570, 1990), I have seen our field grow and have grown with it. My initial work focused on gene therapy for HIV disease and the development of hemophilia gene therapy. I consider myself an agnostic vectorlogist, which permitted me to focus on the application at hand and not the platform. 

For the last 15 years, my research has concentrated on cancer immunotherapy. I have extensively published on T-cell receptor (TCR) gene therapy and was the first author on the initial report where this technology was shown to lead to cancer regression in patients (Science 314:126, 2006). As chimeric antigen receptor (CAR) technology developed, I reported multiple applications of this technology and participated in several CAR clinical trials.

In 2013, I made the switch from academia to industry to lead the immunotherapy efforts at bluebird bio. I currently manage an outstanding group of scientists that are developing the next-generation of engineered T cells for cancer immunotherapy. Our goal is to develop cellular treatments that go beyond standard TCR/CAR-based antigen targeting, and will include additional protein engineering and gene editing to augment both safety and enhance T cell activity within the hostile tumor microenvironment.  

Board & Officers

The ASGCT Board of Directors and the Society's officers have full responsibility for the management, direction and control of the Society.

2019
22nd Annual Meeting
April 29 – May 2 | Washington D.C.
Close